Search Results

● CANDID-CNS™ is the new state-of-the-art AI model for BBB penetration: it achieves 87% AUPRC on bRo5 small molecules compared to 56% by Pfizer’s CNS MPO. ● CANDID-CNS™ distinguishes CNS penetrant stereoisomers at 68% compared to 50% by Pfizer’s CNS MPO. ● Published in the Journal of Chemical Information and Modeling, CANDID-CNS™ presents a breakthrough in AI Drug Discovery by unlocking the potential of bRo5 and stereochemistry to significantly expand the chemical space of small molecules that can be developed into CNS therapeutics.

Roche announced that Hitachi High-Tech and Roche have extended their partnership, committing to at least 10 years of additional collaboration.

RaySearch Laboratories AB (publ) is pleased to announce a milestone in radiotherapy technology where RaySearch’s RayStation®* was used for the world’s first clinical treatment using OXRAY, a new treatment machine from Hitachi.

Effective July 1, 2021 local time, Hitachi Chemical Diagnostics, Inc. is renamed to Minaris Medical America, Inc. and its group company Hitachi Chemical Diagnostics Systems Co., Ltd. is renamed to Minaris Medical Co., Ltd.